Atlas Trials

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Clinical trial NCT04279379 · UNKNOWN

Trial details

NCT number
NCT04279379
Sponsor
Beijing Tongren Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Extranodal NK/T-cell Lymphoma
Start date
2020-04-01
Primary completion
2022-12-31
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.